ストックスクリーナーアプリを入手
0.00
100.00%
-1.60
前日終値:
$1.60
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
$368.00K
当期純損益:
$-75.48M
株価収益率:
0.00
EPS:
-41.8646
ネットキャッシュフロー:
$-56.05M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-70.69%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$1.60
Talis Biomedical Corp Stock (TLIS) Company Profile
Compare TLIS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLIS
Talis Biomedical Corp
|
0.00 | 0 | 368.00K | -75.48M | -56.05M | -41.86 |
|
ABT
Abbott Laboratories
|
109.95 | 191.06B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
349.56 | 133.77B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.24 | 113.29B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.79 | 103.56B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.56 | 48.53B | 6.07B | 1.06B | 1.34B | 1.8063 |
Talis Biomedical Corp Stock (TLIS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-01-07 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-09-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-08-31 | ダウングレード | BTIG Research | Buy → Neutral |
| 2021-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-08-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-09 | 開始されました | BTIG Research | Buy |
| 2021-03-09 | 開始されました | BofA Securities | Neutral |
| 2021-03-09 | 開始されました | JP Morgan | Overweight |
| 2021-03-09 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Talis Biomedical Corp (TLIS) 最新ニュース
TLIS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Los Angeles Daily NewsTalis Biomedical Corporationcommon stock (Nasdaq:TLIS) Stock Quote - FinancialContent
Talis Biomedical Corp (NASDAQ: TLIS)Related Research - intelligentinvestor.com.au
TLIS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces That a Securities Fraud Class Action Lawsuit Was Filed Against Talis Biomedical Corporation - Newsfile
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders Talis Biomedical Corporation (TLIS) Investigation - ACCESS Newswire
TLISTalis Biomedical Corp Latest Stock News & Market Updates - Stock Titan
TALIS BIOMEDICAL CORPORATION (NASDAQ: TLIS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Talis Biomedical Corporation (NASDAQ: TLIS) - ACCESS Newswire
Eligible Talis Biomedical Investors Could Claim a Share of $32.5 Million Settlement - Claim Depot
Baker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical Corp - Yahoo Finance
Talis Biomedical Agrees to Settle Investor Suit for $33 Million - Bloomberg Law News
Biotech Investors Reach $32.5M Deal Over Failed COVID Test - Law360
Talis Biomedical ends Chicago office lease with $3.62 millio fee - Investing.com
Talis Biomedical executive buys $44,240 in company stock - Investing.com
Talis Biomedical settles lawsuit with Kriya Therapeutics - Investing.com
TLIS Stock Price and Chart — OTC:TLIS - TradingView — Track All Markets
Talis Biomedical executive buys $641 in stock - Investing.com
Talis Biomedical agrees to $32.5 million settlement - Investing.com
Talis Biomedical to be delisted from Nasdaq on September 3 - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Talis Biomedical Announces Board Shake-Up Amid Financial Struggles - TipRanks
Press Telegram - FinancialContent
Investors Win Class Cert. Against Failed COVID Test Maker - Law360
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives' - The Business Journals
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors - marketscreener.com
Rustem F. Ismagilov Net Worth (2025) - GuruFocus
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update - FinancialContent
Chemical spill prompts hazmat response, evacuation at Redwood Shores biomedical firm - CBS News
Whittier Daily News - FinancialContent
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) - Stock Titan
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement - FinancialContent
Talis Biomedical Announces 1-for-15 Reverse Stock Split - FinancialContent
Daily Breeze - FinancialContent
Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results | About Us | Oil & Gas Journal - FinancialContent
Talis Announces Fourth Quarter and Full Year 2022 Financial Results - GlobeNewswire
2022 Year-End Securities Litigation Update - Gibson Dunn
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
Talis Biomedical Reports Third Quarter 2022 Financial Results - marketscreener.com
TALIS BIOMEDICAL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - MarketScreener
Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Call Transcript - The Motley Fool
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022 - Yahoo Finance
Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
About Us - FinancialContent
Talis Biomedical to Announce Fourth Quarter and Full Year Financial Results on March 15, 2022 - Yahoo Finance
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
PRN_FinancialWrapper - FinancialContent
Salt Lake City News, Weather, Sports, Breaking News | KUTVShareholder Action Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm - FinancialContent
TLIS LAWSUIT ALERT: Levi & Korsinsky Notifies Talis Biomedical Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
User - FinancialContent
Talis Biomedical Corp (TLIS) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
大文字化:
|
ボリューム (24 時間):